{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:41:03Z","timestamp":1774521663848,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA224018"],"award-info":[{"award-number":["CA224018"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA234181"],"award-info":[{"award-number":["CA234181"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA272426"],"award-info":[{"award-number":["CA272426"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.014","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T01:27:07Z","timestamp":1705800427000},"page":"533-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunocompetent Mouse Models of Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Megan Tien","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.hoc.2023.12.014_bib1","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.014_bib2","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.014_bib3","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.014_bib4","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.4081\/hr.2020.9054","article-title":"The molecular pathogenesis of multiple myeloma","volume":"12","author":"Bolli","year":"2020","journal-title":"Hematol Rep"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.014_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2023.12.014_bib7","article-title":"The Vk\u2217MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversity","author":"Maura","year":"2023","journal-title":"bioRxiv preprint"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.014_bib8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.014_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.014_bib11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41590-021-00947-9","article-title":"Inflammatory stromal cells in the myeloma microenvironment","volume":"22","author":"Sklavenitis-Pistofidis","year":"2021","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.014_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"issue":"18","key":"10.1016\/j.hoc.2023.12.014_bib13","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.014_bib14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4049\/jimmunol.158.3.1108","article-title":"Mouse CD38 is down-regulated on germinal center B cells and mature plasma cells","volume":"158","author":"Oliver","year":"1997","journal-title":"J\u00a0Immunol"},{"issue":"18","key":"10.1016\/j.hoc.2023.12.014_bib15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.014_bib16","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.014_bib17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.014_bib18","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.4049\/jimmunol.112.6.2271","article-title":"Homogeneous immunoglobulins in sera of mice during aging","volume":"112","author":"Radl","year":"1974","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib19","first-page":"31","article-title":"The influence of genetic factors associated with the immunoglobulin heavy chain locus on the development of benign monoclonal gammapathy in ageing IgH-congenic mice","volume":"65","author":"van den Akker","year":"1988","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.014_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.thj.6200052","article-title":"The 5TMM series: a useful in\u00a0vivo mouse model of human multiple myeloma","volume":"1","author":"Asosingh","year":"2000","journal-title":"Hematol J"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib21","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1038\/s41598-018-33396-w","article-title":"The genetic landscape of 5T models for multiple myeloma","volume":"8","author":"Maes","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.014_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.014_bib23","doi-asserted-by":"crossref","first-page":"e0127828","DOI":"10.1371\/journal.pone.0127828","article-title":"Whole Genome Sequence of Multiple Myeloma-Prone C57BL\/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types","volume":"10","author":"Amend","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.014_bib24","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neo.2014.07.002","article-title":"SAMSN1 is a tumor suppressor gene in multiple myeloma","volume":"16","author":"Noll","year":"2014","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.014_bib25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1096\/fba.2020-00027","article-title":"Characterization of the role of Samsn1 loss in multiple myeloma development","volume":"2","author":"Friend","year":"2020","journal-title":"FASEB Bioadv"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.014_bib27","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/leu.2012.113","article-title":"Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow","volume":"26","author":"Van Valckenborgh","year":"2012","journal-title":"Leukemia"},{"issue":"5\u20136","key":"10.1016\/j.hoc.2023.12.014_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","article-title":"Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model","volume":"23","author":"Menu","year":"2006","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.014_bib29","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.neo.2017.09.004","article-title":"DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment","volume":"19","author":"Hewett","year":"2017","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A\u00a0niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.014_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3181\/00379727-101-24970","article-title":"Induction of plasma-cell neoplasms and fibrosarcomas in BALB\/c mice carrying diffusion chambers","volume":"101","author":"Merwin","year":"1959","journal-title":"Proc Soc Exp Biol Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.014_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1034\/j.1600-065X.2003.00061.x","article-title":"Neoplastic development in plasma cells","volume":"194","author":"Potter","year":"2003","journal-title":"Immunol Rev"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.014_bib34","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1172\/JCI69094","article-title":"GP130 activation induces myeloma and collaborates with MYC","volume":"124","author":"Dechow","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.014_bib35","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1073\/pnas.95.5.2429","article-title":"Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1","volume":"95","author":"Zhang","year":"1998","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2 Pt 1","key":"10.1016\/j.hoc.2023.12.014_bib36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0092-8674(82)90137-4","article-title":"Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas","volume":"31","author":"Shen-Ong","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2023.12.014_bib37","first-page":"649","article-title":"Bone lesions produced by transplanted plasma-cell tumors in BALB\/c mice","volume":"28","author":"Kobayashi","year":"1962","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.014_bib38","doi-asserted-by":"crossref","first-page":"e51892","DOI":"10.1371\/journal.pone.0051892","article-title":"A\u00a0novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease","volume":"7","author":"Hofgaard","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.014_bib39","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1172\/JCI200420369","article-title":"Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice","volume":"113","author":"Cheung","year":"2004","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.014_bib40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","article-title":"The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis","volume":"11","author":"Carrasco","year":"2007","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.014_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.014_bib42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.014_bib43","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.014_bib44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T\u00a0cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discovery"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib45","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.014_bib46","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.hoc.2023.12.014_bib47","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2023.12.014_bib48","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.BCD-19-0068","article-title":"Monosomic loss of MIR15A\/MIR16-1 is a driver of multiple myeloma proliferation and disease progression","volume":"1","author":"Chesi","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2020007156","article-title":"Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice","volume":"137","author":"Wen","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.014_bib51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1158\/0008-5472.CAN-10-1057","article-title":"A\u00a0novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23)","volume":"71","author":"Morito","year":"2011","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.014_bib52","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219439120","article-title":"Mouse models of human multiple myeloma subgroups","volume":"120","author":"Winkler","year":"2023","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.014_bib53","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.014_bib54","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"Innate immune response in Th1- and Th2-dominant mouse strains","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.014_bib55","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41598-020-79477-7","article-title":"Elucidating different pattern of immunoregulation in BALB\/c and C57BL\/6 mice and their F1 progeny","volume":"11","author":"Hartmann","year":"2021","journal-title":"Sci Rep"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:18:34Z","timestamp":1760591914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001818"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.014","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunocompetent Mouse Models of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}